GC Therapeutics has appointed Stefan Irion as Chief Scientific Officer (CSO). Irion brings more than two decades of experience translating stem cell science into clinical stage therapeutics.
In his role at GCTx, Irion will lead and direct the company’s research strategy as it advances its differentiated cell therapy pipeline toward the clinic.
His appointment follows the recent addition of Kate Haviland as Board Chair, further strengthening GCTx’s leadership team and positioning the company for its next phase of growth.
Concurrently, co-founder Alex Ng will assume the role of chief innovation officer.
Irion joins GCTx from BlueRock Therapeutics (a wholly-owned, independently operated subsidiary of Bayer), where he served as chief scientific officer and a member of the Executive Committee. At BlueRock, he built and led a research organization of approximately 60 scientists developing cell & gene therapies across multiple therapeutic areas.
Parastoo Khoshakhlagh, CEO and Co-founder of GCTx, said: “Stefan brings deep expertise in developing novel therapeutics, along with exceptional leadership and an innovative perspective. His strong commitment to patients makes him uniquely suited to help drive GCTx’s next phase of growth.”
Irion commented: “Having spent my career working to bring cell therapies from bench to bedside, I’ve seen how much is still possible and how many patients are still waiting,”
GC Therapeutics is a pioneering biotechnology company advancing the next generation of cell-based medicines.